GLP-1 drugs may cause nerve damage from rapid weight loss: first case-control evaluation of peripheral neuropathies | Research

The takeaway

First case-control study investigating GLP-1RA-associated diabetic lumbosacral radiculoplexus neuropathy (DLRPN) and common fibular neuropathy (CFN) linked to rapid weight loss from semaglutide, with NAION precedent suggesting vascular/metabolic nerve injury mechanism.

New nerve damage concern
Beyond optic nerve damage (NAION), GLP-1 drugs may contribute to peripheral neuropathies through rapid weight loss—the first systematic evaluation of this risk

What the researchers found

First case-control evaluation of GLP-1RA-associated DLRPN and CFN. Semaglutide already linked to NAION. Both neuropathies associated with weight loss. Possible mechanism: rapid weight loss → nerve ischemia/compression. Expands GLP-1 neurological safety profile.

Why it matters

As millions lose weight rapidly on GLP-1 drugs, peripheral nerve injuries from weight-related mechanisms may increase. Recognizing this association enables early diagnosis and management.

How the study worked

Case-control study evaluating GLP-1RA exposure in patients with DLRPN or CFN vs controls.

What this study cannot tell us

Case-control design—cannot prove causation. Weight loss itself causes these neuropathies. Difficult to separate drug from weight loss effect. Specific results not detailed in abstract preview.

How to read the evidence

Case-control study. First investigation of this association.

When this study was published

Published in 2025.

The bigger picture

This reveals another dimension of GLP-1 drug neurological safety beyond the NAION signal. Rapid weight loss may cause multiple types of nerve damage through shared vascular/compression mechanisms.

Questions still open

Is the neuropathy risk from the drug or from rapid weight loss?
Should weight loss speed be limited on GLP-1 drugs to protect nerves?
Are other peripheral neuropathies also associated with GLP-1RA use?

Common questions

Can weight loss drugs cause nerve damage?

This study is the first to formally evaluate whether GLP-1 drugs are associated with specific peripheral neuropathies. Rapid weight loss (from any cause) can damage nerves through compression or reduced blood flow. The question is whether GLP-1 drugs add to this risk beyond what weight loss alone would cause.

What symptoms should I watch for?

If you develop new pain in your lower back or legs, weakness in your feet (difficulty lifting the foot—foot drop), numbness, or tingling while losing weight on GLP-1 drugs, report these to your doctor. These could be signs of peripheral neuropathy that need evaluation.

Read the original research

GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.

Neurology, 105(3), e213916

View on PubMed ↗Publisher’s paper ↗

Citation

Triplett, James D; Pinto, Marcus V; Young, Nathan P; Staff, Nathan P; Chinmay, Marathe S; Horowitz, Michael; Aragon Pinto, Catarina; Laughlin, Ruple S; Shouman, Kamal; Berini, Sarah E; Mauermann, Michelle L; Dubey, Divyanshu; Mandrekar, Jay; Dyck, P James B; Klein, Christopher J. (2025). GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies: A Case-Control Evaluation.. Neurology, 105(3), e213916. https://doi.org/10.1212/WNL.0000000000213916